Remdesivir has “little or no effect on mortality” for patients hospitalized with coronavirus and it doesn’t seem to help Covid-19 patients recover any faster, either.

A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...

Medicines designed to treat COVID-19 won't be available for months, so doctors are looking to drugs already approved for treating other diseases. Coronavirus drugs: Where we are and what we know ...

A new study from researchers at Wake Forest University School of Medicine is shedding light on how scientific evidence and ... Research highlights media misrepresentation of COVID-19 drug efficacy.

There are also some drugs that have been approved for one purpose, and they may have some efficacy against COVID-19. So there's actually a heartburn drug that's being tried.

A new class of drugs could prevent resistant COVID-19 variants, study finds. ScienceDaily . Retrieved June 2, 2025 from www.sciencedaily.com / releases / 2023 / 03 / 230308171657.htm ...

The SARS-CoV-2 macro domain protein bound to small molecule fragments that could be the basis of novel antiviral drugs. Editor’s note: A manuscript detailing the findings was posted to the bioRxiv ...

“Future phase III trials will soon confirm or refute the usefulness of this candidate drug as a backbone treatment for COVID-19.” The study authors also highlight some limitations to their study.

The study looked at a variety of literature for drug therapies for COVID-19 -- including hydroxychloroquine, remedesivier, tocilizumab and steroids -- on PubMed.

Moderna’s Covid-19 vaccine showed 93% efficacy against symptomatic disease through six months, and the company expects to complete its application for full approval from the US Food and Drug ...

That means the experimental drug ought to work equally well no matter how the coronavirus mutates, and the study suggests it does, Wang said. The virus’ shape-shifting ways have ratcheted up the ...